ALX Oncology Holdings Inc. (ALXO) annual balance sheet — 8-year assets, liabilities & equity history
ALX Oncology Holdings Inc. (ALXO) balance sheet — 8-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Total Current Assets | 143.46M | 50.73M | 134.35M | 188.66M | 270.97M | 367.02M | 435.99M | 9.81M | 10.21M |
| Cash & Short-Term Investments | 138.23M | 44.79M | 127.76M | 182.74M | 266.21M | 363.67M | 434.22M | 9.02M | 8.26M |
| Cash Only | 22.69M | 16.37M | 17.57M | 22.41M | 48.82M | 363.67M | 434.22M | 9.02M | 8.26M |
| Short-Term Investments | 115.54M | 28.42M | 110.19M | 160.33M | 217.38M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 298K | 892K | 0 | 0 | 0 | 0 | 536K | 932K |
| Days Sales Outstanding | - | - | - | - | - | - | - | 40.79 | 164.58 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 5.64M | 5.7M | 5.92M | 4.76M | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 17.36M | 8.32M | 13.42M | 53.89M | 35.52M | 13.16M | 62K | 867K | 956K |
| Property, Plant & Equipment | 1.27M | 1.2M | 9.63M | 10.84M | 9.81M | 3.47M | 52K | 860K | 956K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | 22.73x | 5.58x | 2.16x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 53.26M | 3.49M | 3.52M | 35.41M | 16.7M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 946K | 3.63M | 267K | 7.64M | 9.01M | 9.69M | 10K | 7K | 0 |
| Total Assets | 160.82M | 59.05M | 147.78M | 242.55M | 306.49M | 380.18M | 436.05M | 10.68M | 11.16M |
| Asset Turnover | 0.00x | - | - | - | - | - | 0.00x | 0.45x | 0.19x |
| Asset Growth % | 0.72% | -60.04% | -39.08% | -20.86% | -19.38% | -12.81% | 3984.43% | -4.37% | - |
| Total Current Liabilities | 14.78M | 24.55M | 18.5M | 36M | 28.32M | 15.29M | 6.2M | 4.98M | 1.87M |
| Accounts Payable | 3.02M | 4.91M | 4.5M | 8.59M | 8.07M | 3.76M | 4K | 3.75M | 697K |
| Days Payables Outstanding | 11.18K | - | - | - | - | - | 1.36 | 313.77 | 135.32 |
| Short-Term Debt | 0 | 5.22M | 435K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 14.42M | 5.97M | 6.7M | 4.72M | 3.53M | 2.13M | 1.06M | 369K |
| Current Ratio | 9.71x | 2.07x | 7.26x | 5.24x | 9.57x | 24.00x | 70.28x | 1.97x | 5.45x |
| Quick Ratio | 9.71x | 2.07x | 7.26x | 5.24x | 9.57x | 24.00x | 70.28x | 1.97x | 5.45x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 9.86M | 8.51M | 15.66M | 16.84M | 14.7M | 1.84M | 5K | 5.97M | 136K |
| Long-Term Debt | 9.71M | 0 | 9.47M | 9.64M | 9.39M | 0 | 0 | 5.42M | 0 |
| Capital Lease Obligations | 0 | 0 | 5.16M | 5.98M | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 152K | 8.51M | 1.03M | 1.22M | 5.31M | 1.84M | 5K | 412K | 0 |
| Total Liabilities | 24.63M | 33.06M | 34.16M | 52.84M | 43.02M | 17.13M | 6.21M | 10.95M | 2.01M |
| Total Debt | 9.71M | 5.22M | 16.98M | 17.2M | 10.43M | 742K | 0 | 5.42M | 0 |
| Net Debt | -12.98M | -11.16M | -589K | -5.21M | -38.39M | -362.93M | -434.22M | -3.6M | -8.26M |
| Debt / Equity | 0.07x | 0.20x | 0.15x | 0.09x | 0.04x | 0.00x | - | - | - |
| Debt / EBITDA | -0.12x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.16x | - | - | - | - | - | - | - | - |
| Interest Coverage | -73.83x | -62.48x | -76.99x | -101.75x | -517.56x | -6420.85x | -53.84x | -913.71x | - |
| Total Equity | 136.19M | 25.98M | 113.62M | 189.71M | 263.46M | 363.05M | 429.85M | -276K | 9.15M |
| Equity Growth % | 38.45% | -77.13% | -40.11% | -27.99% | -27.43% | -15.54% | 155840.94% | -103.01% | - |
| Book Value per Share | 1.00 | 0.48 | 2.18 | 4.41 | 6.47 | 9.01 | 10.79 | -0.01 | 0.42 |
| Total Shareholders' Equity | 136.19M | 25.98M | 113.62M | 189.71M | 263.46M | 363.05M | 429.85M | -276K | 9.15M |
| Common Stock | 138K | 54K | 53K | 50K | 41K | 41K | 40K | 3K | 3K |
| Retained Earnings | -758.72M | -722.82M | -621.12M | -486.27M | -325.47M | -201.99M | -118.52M | -72.78M | -53.54M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -224K | 28K | 275K | 256K | -845K | 0 | 0 | 0 | -1.02M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ALXO stock.
As of 2025, ALX Oncology Holdings Inc. (ALXO) had total assets of $59.0M including $50.7M in current assets.
ALX Oncology Holdings Inc. (ALXO) carries total debt of $5.2M, offset by $44.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
ALX Oncology Holdings Inc. (ALXO) has total shareholders' equity (book value) of $26.0M ($0.48 book value per share). Book value represents the net worth of the company belonging to common stock holders.
ALX Oncology Holdings Inc. (ALXO) reported a current ratio of 2.07x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.